A new category of breast cancer patients with reduced HER2 expression has recently been identified, known as HER2-low, defined as IHC 1+ or IHC 2+ ISH non-amplified, which represents 45–64% of BC (4) [12]. Here, ERBB2 is linked to breast carcinoma.